Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T16:15:47.877Z.
Calculation as of: 2026-10-06T16:15:47.877Z.
Quote observation: 2026-10-06T16:15:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a5b8a39003d923715743cc0d1a2c59dcf36f227505f31b08d3d275f4059bcabd
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Attovia Therapeutics, Inc.
Market Cap
$781.61M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$779.56M
Operating Cash Flow Yield
N/A
TTM Avg
46.70%
3Y Avg
46.70%
5Y Avg
28.34%
Market Cap
$788.34M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$789.07M
Operating Cash Flow Yield
N/A
TTM Avg
1.73%
3Y Avg
1.73%
5Y Avg
1.73%
Market Cap
$771.14M
Operating Cash Flow Yield
7.22%
TTM Avg
8.35%
3Y Avg
7.91%
5Y Avg
6.12%
Market Cap
$795.90M
Operating Cash Flow Yield
73.28%
TTM Avg
47.32%
3Y Avg
42.03%
5Y Avg
31.48%
Market Cap
$802.16M
Operating Cash Flow Yield
N/A
TTM Avg
0.41%
3Y Avg
2.06%
5Y Avg
3.27%
Market Cap
$763.85M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | $781.61M | N/A | N/A | N/A | N/A |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $779.56M | N/A | 46.70% | 46.70% | 28.34% |
| Sana Biotechnology, Inc. (SANA)vs › | $788.34M | N/A | N/A | N/A | N/A |
| Geron Corporation (GERN)vs › | $789.07M | N/A | 1.73% | 1.73% | 1.73% |
| Mesa Laboratories, Inc. (MLAB)vs › | $771.14M | 7.22% | 8.35% | 7.91% | 6.12% |
| Apnimed, Inc. (APMD)vs › | $792.48M | N/A | N/A | N/A | N/A |
| AdaptHealth Corp. (AHCO)vs › | $795.90M | 73.28% | 47.32% | 42.03% | 31.48% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $802.16M | N/A | 0.41% | 2.06% | 3.27% |
| Design Therapeutics, Inc. (DSGN)vs › | $763.85M | N/A | N/A | N/A | N/A |
| InMode Ltd. (INMD)vs › | $805.46M | 11.00% | 10.22% | 10.24% | 8.00% |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
